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ABSTRACT
A primary bottleneck in DNA-sequencing operations is the capacity of the
detection process. Although today's capillary electrophoresis DNA sequencers are faster,
more sensitive, and more reliable than their precursors, high purchasing and running costs
still make them a limiting factor in most laboratories like those of the Broad Institute. It is
important to run those sequencers as efficiently as possible to reduce costs while producing
robust assemblies. Polymer media for electrophoresis is the most important determinant for
sequencing throughput. This thesis investigates the effect of polymer media on the
performance of Applied Biosystems (ABI) 3730xl, the de-facto standard of DNA
sequencers and develops analysis procedures for ABI3730xl system and its data.
Due to its use in the human genome project (HGP), ABI has established a
monopolistic position in the DNA-sequencing tool industry. As the de-facto standard of
DNA sequencers ABI3730xl is highly automated, well-optimized, and black-boxed,
despite the importance of higher throughput sequencing for diagnostic applications, third
parties have found it difficult to improve sequencing methods. This thesis also conducts an
analysis of the DNA-sequencing tool industry to discuss how ABI has established current
monopolistic status, what kind of business model would be attractive for ABI in the
post-HGP period, how new companies can successfully enter this industry, and how they
can keep improving DNA-sequencing throughput along the line of "Moore's law".
Thesis Supervisors:
Roy E. Welsch
Professor of Statistics and Management Science
Patrick S. Doyle
Assistant Professor of Chemical Engineering
2
Table of Contents
Acknowledgements 5
1. Introduction 6
2. Background 8
2.1 Broad Institute Overview 8
2.2 Genome-sequencing Operation Overview 11
2.2.1 Operation Process 11
2.2.2 Genome-sequencing Technology 13
3. Improvement of the Electrophoretic Genome-sequencing Process 16
3.1 Introduction 16
3.2 Research History of Polymer Media for DNA-sequencing 18
3.2.1 Linear Water-Soluble Polymers 18
3.2.2 Thermo-Sensitive Polymers and Polymers with Higher-order Structure 22
3.2.3 Summary of Past Polymer Research 24
3.3 Experimental Section 25
3.3.1 Selection of Polymers 25
3.3.2 Capillary Electrophoresis 25
3.3.3 Chemical Analysis 26
3.4 Results and Discussions 28
3.4.1 Establishment of Experimental Protocol for Polymer Research 28
3.4.2 POP7 35
3.4.3 DMA 41
3.4.4 LPA 44
3.4.5 Chemical Analysis of POP7 47
3.4.6 Polymer Mixtures 52
3.5 Possible Approaches for the Future 55
3.6 Summary 57
3
4. Analysis of the Genome-Sequencing Tool Industry 58
4.1 Introduction 58
4.2 History of Genome-Sequencing Technology 58
4.3 Emergence of the Genome-Sequencing Tool Industry 63
4.4 Analysis of the Genome-Sequencing Tool Industry 65
4.4.1 Industry S-curves 65
4.4.2 Uniqueness and Complementary Assets to Create and Capture Value 66
4.4.3 Industry Structure - Present and Future 70
4.4.4 Value Chain and Boundaries 73
4.4.5 Strategy for the Future of ABI 74
4.5 Summary 75
5. Conclusion 76
4
Acknowledgements
The author wishes to acknowledge the Leaders for
Manufacturing Program for its support of this work.
He would also like to thank Robert Nicol, Patrick Cahill,
James Meldrim, Karen Foley and the group of Technology
Development at the Broad Institute.
Finally, he would like to thank his wife, Naoko, for her
continuous support during his busy but fun days in
Cambridge.
5
1. Introduction
Huge technological advancements in information technology and a deeper understanding
of biomaterials in the past twenty years have allowed for the discovery of the entire genetic
information of humankind. The Whitehead Institute Center for Genomic Research was a
primary contributor to this achievement. In the 1990s, during the Human Genome Project,
its sequencing operation played a key role in rapidly improving genome-sequencing
throughput. The Whitehead Institute has recently combined research efforts with the
Massachusetts Institute of Technology (MIT) and Harvard University to form the Broad
Institute.
Even after the completion of the Human Genome Project in 2003, increased sequencing
throughput at an affordable cost is critical to the realization of advanced and economical
genomics-based medications. However, without tangible economical returns in the near
future, research institutes and related industries in the genome-sequencing arena are
evidently frustrated. Not only is the next incremental technological step necessary to move
the field forward but also an appreciation for past and potential future balances of power in
the arena would be enough to drive such a highly technology-driven industry toward future
medical applications.
The Broad Institute has improved throughput of genome-sequencing operations with an
eye toward future healthcare applications. A primary bottleneck of the current sequencing
operation is the capacity of the sequence detection process using the "Genome Sequencer,"
a key instrument in reading base code sequence for DNA. Many scientists and engineers in
the Broad Institute are conducting research not only on multicapillary electrophoresis, the
current sequencing technology, but also on next-generation technologies, to increase the
capacity of the sequence detection process.
This thesis is based on a Leaders for Manufacturing (LFM) internship at the Broad
Institute, where the author worked with the genome sequencer in terms of both
technological and business aspects. The author investigated polymer media of the current
genome sequencer to improve its operation efficiency. He also conducted technology and
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business analyses for the genome-sequencing tool industry and made attempt to forecast
the future of the industry.
The thesis proceeds as follows:
Chapter 2, "Background," provides information on the Broad Institute as well as modem
genome-sequencing technology. It concludes with a discussion of the detection phase of
the genome-sequencing process, providing insight into the multicapillary electrophoresis
procedure.
Chapter 3, "Improvement of Electrophoretic Genome-sequencing Process," consists
of the engineering portion of this thesis, investigating possibilities for improving the
efficiency of current genome-sequencing. The discussion focuses on the role of polymer
media in multicapillary electrophoresis technology.
Chapter 4, "Analysis of the Genome-sequencing Tool Industry," examines the business
perspective of genome-sequencing technology with an analysis of research history and the
emergence of the genome-sequencing tool industry. The discussion includes how the
monopoly status of Applied Biosystems, Inc. (ABI) has been successfully established,
whether ABI's dominance will continue in the future, and how the industry can be
developed in the future.
Chapter 5, "Conclusion," ties the discussion of the preceding chapters together and offers
some perspectives on how conclusions can be applied outside the field of genomics.
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2. Background
2.1 Broad Institute Overview
The Broad Institute is the collaborative research organization between MIT, Harvard
University, and the Whitehead Institute; its official name is "The Eli and Edythe L. Broad
Institute of MIT, Harvard University and its affiliated hospitals, and Whitehead Institute."
In June 2003, philanthropists Eli & Edythe Broad of Los Angeles gave $100 million to
create an institute with MIT, Harvard, and Whitehead to fulfill the genome's promise for
medicine. The institute begin its activity later that same year. Figure 1 shows the mission
statement of the Broad Institute.
o Our scientific mission is:
To create tools for genomics medicine and make them
broadly available to the scientific community
To apply these tools to propel the understanding and
treatment of disease
o Our organizational mission is:
--- To enable collaborative projects that cannot be
accomplished solely within the traditional setting of
individual laboratories
To empower scientists through access to cutting-edge tools
Figure 1 Mission Statement of the Broad Institute'
The Broad Institute consists of two kinds of organizations called "Programs" and
"Platforms." Programs are scientific research groups that focus on specific problems, led
by researchers called Principal Investigators. Four Programs currently exist; they are Cell
Components, Chemical Biology, Cancer Genomics, and Medical and Population
Genomics. For example, the Cell Components Program, where Dr. Eric Lander is the
Principal Investigator, focuses on identifying and monitoring functional components of the
cell and applying this information to the basic understanding of human diseases.
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I http://www.broad.mit.edu/
Platforms are responsible for the operation and development of Broad's common
technology bases. "Program" research projects often include "platform" researchers and
engineers to access Broad's shared technologies. Out of the four technological platforms,
the author spent his internship at the Genome-sequencing and Analysis (GS&A) platform,
which is one of the genome-sequencing centers with the world's highest throughput and its
responsible for the implementation and technological development of Broad's
genome-sequencing process.
"Programs"
:rIncipi1 Dr. E;ic Lander D." Stuart Sc;treibr Dr. Todd Goulb Dr. Davidi Alsuier
Investigators , (Whitehead. Al 1, Biology) (Hf.rvard Bo!ihem) lavward M.aefiai) lHarrd Medal. MGJH)
"Platfrms X Genome sequencing ,
I ' l l :*~.?J? PoSu...opply
igu e OrgTechnooy Development (11 4) pport
Figure 2 Organizational structure of the Broad Institute
The author conducted his internship at the Technology Development Group, or "Dev,"
under the Sequencing Operation Department of GS&A. Figure 2 shows the organizational
structure of the Broad Institute. Dev is part of the technical support team for the Production
Sequencing group and the Molecular Biology Production group. Dev does not conduct
cutting-edge research but rather solves problems around the current DNA-sequencing
process.
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Improving the throughput of genome-sequencing and reducing the cost of genetic
information are still critical to the future of genomics medication or tailored medication.
As much as the Human Genome Project has dramatically reduced the cost of sequencing,
the cost to sequencing one human's DNA still remains around $10 million, as shown in
Figure 3. One of Dev's key tasks is to reduce the sequencing cost so that it is affordable for
individual medication service. Thus, Dev currently addresses a wide range of research
projects in order to improve sequencing throughput - from the optimization of running
conditions to the evaluation of next-generation technology developed by technology
start-up companies.
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Figure 3 "Moore's law" applied to genome-sequencing technology 2
2 Courtesy of Rob Nicol, Director of Sequencing Operations department, Broad Institute
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A
2.2 Genome-sequencing Operation Overview
2.2.1 Operation Process
Figure 4 shows three major steps in the DNA-sequencing operation at the Broad Institute -
molecular biology, core sequencing, and finishing. The Sequencing Operation department
oversees the molecular biology process, handled by the Molecular Biology Production
group, and core sequencing process, performed by Production Sequencing group, while the
Finishing department is responsible for the finishing process. (See Figure 2 for the
organizational structure of the Genome-sequencing platform.)
The molecular biology process consists of three sub-processes: DNA preparation, ligation,
and transformation. In DNA preparation, a DNA sample, which typically includes three
billion base pairs (bp) for a human genome, is enzymatically chopped up into around
four-thousand bp fragments. These fragments, called "plasmids," are embedded in the
circular chromosome of E. Coli and allowed to proliferate on agar plates during ligation
and transformation processes. The multiplied plasmids are then extracted from the E. Coli
cell and purified to prepare a sample for the succeeding processes called sequencing
reaction and detection, during which the DNA code is read by the electrophoretic
technique. Schematic diagrams for the molecular biology process and the core sequencing
process are shown in Figures 5 and 6 respectively.
Genome
DNA Database
.IMolecular Core 
, Bology J Sequencing
CCGTG
ii i i
Focus of this Internship
Figure 4 Three major processes in the DNA-sequencing operation
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Figure 6
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2.2.2 Genome-Sequencing Technology3
The currently-accepted genome-sequencing procedure is based on the Sanger method,
which was developed between 1964 and 1977 by Professor Fred Sanger of the University
of Cambridge. After some technological improvements, the modified Sanger method was
established in late 1990s. 4 Due to its use of reaction enzymes and
Dideoxyribotriphosphoric acid (dd-NTP), the Sanger method is also called the "Enzyme
method" or the "Dideoxy method."
Figure 7 illustrates the basic idea behind the DNA-sequencing process that is based on the
modified Sanger method. This process follows two steps:
* Prepare various lengths of complementary DNA (c-DNA) fragments using the
original single-strand DNA as a template.
* Read out the base code of the replicated c-DNA to learn the base sequence of the
original DNA sample.
In the "sequence reaction" process, polymerase chain reaction (PCR) is used to duplicate
multiple c-DNA fragments.5 In the Sanger Method, a small amount of reaction terminators
(dd-NTP) are used with reaction monomers (Deoxyribotriphosphoric acid, d-NTP) for
PCR. Both monomers and terminators are comprised of nucleic acids with four different
bases, i.e. adenine (A), cytosine (C), guanine (G), and thymine (T). Each type of dd-NTP is
labeled with different color dyes through chemical modification. Polymerization continues
while d-NTP is attached to the end of an active c-DNA chain. The reaction terminates once
dd-NTP reacts instead of d-NTP. Finally, various lengths of c-DNA fragments, capped
with either an A, C, G, or T-type of dd-NTP, are synthesized.
3 Encyclopedia for Biotech and Genomics (in Japanese); Mitsubishi Research Institute; Mitsubishi
Kagaku Institute of Life Science, Eds., Toyo Keizai Inc.: Tokyo, 2004.
4 More history of the development of the DNA-sequencing technique is discussed in Chapter 4.
5 This experimental method proliferates a particular region of a small amount of DNA molecules using
a heat-stable enzyme, called DNA polymerase. K. B. Mullis, a researcher at the Cetus Corporation,
invented PCR. He was awarded the Nobel Prize in Chemistry in 1993 for this achievement, only seven
years after he first published his ideas.
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"Sequencing detection" is the process by which the labeled c-DNA fragments are read out
one by one, from short to long. The technique called electrophoresis is used for this
procedure. Figure 8 shows the basic principle behind DNA electrophoresis. The multiplied
c-DNA fragments are injected into a capillary filled with water-soluble polymers to be
used as a sieving media. The c-DNA fragments are charged with electricity; under an
electric field, they travel through the capillary toward the other end. Since shorter
fragments experience less resistance from the polymer media, they travel through the
capillary faster than the longer ones. At the end of the capillary, a laser beam excites the
labeling dye and the luminescent intensity for each of the four colors is recorded as a
function of time. In the current sequencing procedure, the instrument called "DNA
sequencer" automatically carries out this process. Figure 9 shows the external appearance
of the de facto standard of DNA sequencers, ABI3730xl.
DNA sample to be read
5'- (1;X ) 3'j57X3X~iX~-3,
Complementary DNA
(c-DNA) e X
Read labeled dd-NTP . 'j
from short
to long c-DNA
el"" O 
Figure 7
PCR
(Polymerase Chain Reaction)
-Primer (Initiator)
·Polymerase (Catalvst}
·Monomer (d-NTP)
Terminator (dd-NTP)
Outline of the DNA-sequencing procedure using Sanger's method
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------- A
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Figure 8
Figure 9
Detector
CThA ...
DNA Sequence
Data
Outline of genome-sequencing with multicapillary electrophoresis
External appearance of ABI3730xl
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3. Improvement of the Electrophoretic Genome-sequencing
Process
3.1 Introduction
Throughput of DNA-sequencing operations has been vastly improved during the past
fifteen years. It has become high enough to finish the human genome project a few years
earlier than originally scheduled. Nevertheless, improvement should continue with an eye
toward diagnostic and pharmaceutical applications.
The capacity of the sequence detection process is a primary obstacle to the sequencing
operation. Although today's multicapillary electrophoresis DNA sequencers are faster,
more sensitive, and more reliable than their precursors, high economic and operational
costs still make them prohibitive for most laboratories like those of the Broad Institute's. It
is important to run the sequencers as efficiently as possible in order to reduce costs while
still producing robust assemblies. For instance, the cost to purchase the ABI3730xl is
$380,000 per unit. Designated consumables, such as polymers and buffers, drive
operational costs even higher. 6 The Broad Institute operates ninety-six units of
ABI3730x1 twenty-four hours a day throughout the year. Nevertheless, sequencing
detection remains the bottleneck in the total operation process.
The main goal of this project is to improve the operational efficiency of ABI3730xl. Since
this instrument employs capillary electrophoresis to sequence DNA, both data quality and
operational efficiency depend completely on the performance of electrophoresis. Past
research showed that there is a trade off in the relationship between migration speed
(sequencing time) and data resolution. The faster the sequencing would run, the lower the
quality in data resolution. Operational conditions, such as electric field and temperature,
also affected this relationship. Although changing the polymer media is an expected and
effective way to solve the poor ratio between speed and resolution, it has never been
examined at Broad. Hence, the author tried to resolve possible further improvements to the
sequencing efficiency by replacing POP7, the default polymer media of ABI3730xl.
6 For example, the Broad Institute annually spends more than $400,000 to purchase the polymer, POP7,
from ABI.
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Before the examination of various polymers began, however, some issues required
clarification. Since no one at Dev was familiar with previous research on polymer media in
DNA electrophoresis, it was necessary to examine the research history. In order to use a
different polymer on the 3730xl, the instrument's ability to work even with polymers quite
different from POP7 had to be assured. The ingredients of POP7 also had to be identified
for comparison. Thus, this project followed these four steps:
1. Examine past research efforts on polymer media
2. Establish a new experimental protocol to handle other polymers
3. Analyze the chemical composition of ABI's default polymer (POP7)
4. Run genome-sequencing using several polymer materials and study their performance
17
3.2 Research History of Polymer Media for DNA-sequencing
Much research on polymer media in DNA capillary electrophoresis was conducted in the
late 1990s. Starting with linear polyacrylamide, researchers dealt with various
water-soluble polymers as well as more complicated polymers.
3.2.1 Linear Water-Soluble Polymers'
To obtain a longer read length, the following three characteristics should be considered
when choosing a polymer. First, high hydrophilicity allows polymer chains to expand
sufficiently in water and to help forming a robust polymer network. Second, high
molecular weight also allows polymer chains to form a polymer network robust enough to
filter even long DNA fragments. Third, high polymer concentration is required to make the
pore size of the network small enough and to give better peak resolution of shorter
fragments. Figure 10 illustrates these three requirements for polymer media in DNA
electrophoresis.
Effect of Hydrophilicity
Less hydrophilic polymer
· Smaller free volume
· Poor network
* Lower viscosity
* More adsorption
ighly hydrophilic polyme
Larger free volume
· Easier to form network
* Higher viscosity
* Less adsorption
Figure 10
Effect of Concentration
High concentration
* Small pore size
* Good filtration
* Higher viscosity
r..g ' - r er Istize
... :) :Lare pore size
· Poor filtration
*Lower viscosity
Relationship between polymer conformation and solution property
However, some trade-offs exist with these three features. Polymers that fulfill all three
requirements make highly viscous solutions, which are difficult to inject into
micro-capillaries. Sequencing throughput decreases with concentrated polymer solutions,
7 Albarghouthi, M.N.; Barron, A.E., Electrophoresis. 2000, 21, 4096-4111
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since the migration speed of DNA fragments becomes slower. Additionally, polymer chain
expansion due to high hydrophilicity does not have the benefit of being self-coating. Bare
fused-silica capillaries cannot be used without pre-coating the interior with a polymer
because arising electro-osmotic flow lowers the peak resolution. By adsorbing more onto
the capillary interior and eliminating the cost-consuming pre-coating process, less
hydrophilic polymer is desirable.
To solve for such trade-offs, various water-soluble polymers have been tested in
DNA-sequencing. The choice of polymer was often arbitrary and empirical, primarily
because the mechanism of DNA separation in uncross-linked polymer solutions is not fully
understood. Table 1 lists the chemical structures of the major polymers that have been
tested for this application.
Linear Polyacrylamide, or LPA, is considered one of the best performing polymers in
terms of long read-length and short separation time due to its high water solubility and
moderately attractive interaction with DNA molecules. However, LPA's high viscosity is a
disadvantage in the injection process. In addition, since LPA does not have self-coating
properties, the capillary manufacturing cost increases because of the need to pre-coat.
Optimal results were obtained with a polymer media comprising 0.5% 270kDa LPA and
2% 17MDa LPA. This formulation delivered a read-length of 1,300bp at 98.5% accuracy
in 2 hours at 70C and 125V/cm.8 LPA is commercially used with the LongReadTM Matrix
for Amersham Biosciences' MegaBACETM sequencer.9
8 Zhou, H.; Miller, A.; Sosic, Z.; Buchholz, B.; Barron, A. E.; Kotler, L.; Karger, B. L., Anal. Chem.
2000, 72, 1045-1052
9 Amersham Biosciences Website,
http://www4. amershambiosciences. com/aptrix/uppO1077. nsf/Content/na_homepage
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Table 1 Major water soluble polymers used for DNA-sequencing by capillary
electrophoresis7
Polymer Chemical Structure
H
N-H
LPA or
N--CH3
PDMA C:
PEO t OCH 2-- CH4n
PVP
CHLCH4
PEG F2CIO-CH-CH2CF 2 +
(End-capped)
m=6ot8
\ .CH2.,,OH l
--CH2 CH2Poly(AAP) n
tCH2-n
HEC
n
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Poly(N,N'-dimethylacrylamide), or DMA, is slightly more hydrophobic than LPA. Thus,
DMA's general capacity as a capillary electrophoresis polymer is inferior to that of LPA.
On the other hand, even bare silica capillaries can be used with DMA, since it can adsorb
onto the inner wall of capillaries. Ramakrishna Madabhushi of ABI eagerly studied DMA
as a DNA-sequencing matrix, focusing on this self-coating feature.'" ABI holds a basic
patent on any water soluble polymers with self-coating features." Since ABI declared
that POP, the polymer matrices for its sequencing instruments, has self-coating features, it
has been widely believed that POP consists of DMA. However ABI has never released any
part of POP's ingredients. Excerpts from related review articles state, "The 3 7 0 0TM
instrument uses a separation matrix that is based on relatively low molar mass, linear
polydimethylacrylamide, commercially known as POP,"7 and "PDMA ... is also widely
used (POP4, 5, 6, Applied Biosystems)."' 2
The best results for DMA were up to 800 bases with a resolution limit of 0.5 (and 1,000
bases with a resolution limit of 0.3) and migration time of 96 minutes, which was achieved
by using 2.5% w/v polymer, 15OV/cm separation electric field, and 60 cm effective
separation length at room temperature. 3
Other water soluble polymers listed in Table 1 have electrophoresis performance inferior to
both LPA and DMA. For instance, while PEO gives a relatively long read-length, seven
hours were required to achieve the separation, which is very long compared to the one hour
run time needed for LPA to achieve the same read-length.'4 PVP and HEC only give
read-lengths shorter than that of LPA.
3.2.2 Thermo-Sensitive Polymers and Polymers with Higher-order
Structure' 5"12
10 Madabhushi, R. S., Electrophoresis. 1998, 19, 224-230.
1l Madabhushi, R. S.; Menchen, S. M.; Efcavitch, J. W.; Grossman, P. D., US Patent 5,567,292, 1996
12 Barbier, V.; Viovy, J.-L.; Current Opinion in Biotechnology. 2003, 14, 51-57
'3 Song, L.; Liang, D.; Fang, D.; Chu, B.; Electrophoresis. 2001, 22, 1987
14 Salas-Solano, O.; Carrilho, E.; Kotler, L.; Miller, A. W.; Goetzinger, E.- Sosic, Z.; Karger, B. L.;
Anal. Chem. 1998, 70, 3996-4003
'5 Buchholz, B. A.; Shi, W.; Barron, A. E.; Electrophoresis. 2002, 23, 1398-1409
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As described in the previous chapter, one problem with linear water-soluble polymers is
the inverse relationship between peak resolution and solution viscosity. Raising
hydrophilicity, molecular weight, or concentration to produce a higher resolution increases
solution viscosity. Some attempts to change the viscosity between injecting the solution
and running the electrophoresis have been tried.
One approach utilizes polymers whose water solubility and solution viscosity depend on
temperature. For example, Poly(N,N'-isopropylacrylamide) (PNIPAM) and
Polypreneoxide (PPO) show such a temperature dependency. PNIPAM has a transition
temperature solubility (lower critical solution temperature or LCST) around 30°C.
PNIPAM dissolves in water, and, thus, its solution viscosity increases below LCST, while
the solution becomes less viscous above LCST. Therefore, the problem was expected to be
solved by applying different temperatures at polymer injection and during electrophoresis.
Several studies based on this idea were conducted. However, since hydrophilicity of
PNIPAM is lower than DMA, even when below LCST, electrophoretic performance was
much worse than for polymers like LPA and DMA.
The other approach uses highly structured copolymers, such as a block copolymer and a
graft copolymer. For example, LPA-g-PNIPAM copolymer, which consists of an LPA
main chain and a short PNIPAM graft chain, has interesting features, such as a
solution-hydrogel transition driven by temperature.' 6" 7 (See Figure 1 lB.) Utilizing this
feature, it would be possible to inject a less viscous LPA solution in low temperature and
then raise the temperature to form a hydrogel for electrophoresis. This polymer would also
adsorb onto the capillary wall anchored by the PNIPAM graft polymer. This approach
would be useful if the polymer structure could be freely controlled. However, good results
have not been observed with this class of polymers, mainly because polymerization
techniques have not yet been developed. For example, if high molecular weight
water-soluble block and graft copolymers, such as LPA-DMA, PEO-PPO, and LPA-PPO,
could be easily synthesized, they should be quite useful for this sort of use.
16 Barbier, V.; Buchholz, B. A.; Barron, A. E.; Viovy, J.-L. Electrophoresis. 2002, 23, 1441-1449
17 Below LCST, PNIPAM hydrophilicity is high enough to allow the polymer to dissolve, whereas
above LCST, PNIPAM becomes hydrophobic enough to aggregate and cause gelation.
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LPA -g- PNIPAM graft copolymer
Low
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Lover Critical Solution
Tempeafture (LCST)
T-30C
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""/ ,'3E:
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Solubility
High
Low
a, LPA main-chain
PNIPAM graft
T<30: Solution
Low Viscosity
JA- Ge
T>30: Gel
High Viscosity
Figure 11 Application of thermosensitive polymers. A,
with LCST; B, LPA-g-PNIPAM graft copolymer
Thermosensitive polymer
23
...I.............  .... ........ .. ......... ... ........ .. .. -- -- -- - - -- --- - -- - ......... .. ... .. ...........  .. ..... ... .... .. .. ........ ... .. ..........  ... ........ ...... 
PNVIPAM
II I
1,
3.2.3 Summary of the Past Polymer Research
LPA has achieved the highest separation capability, even though the cost consuming
pre-coating process is required. DMA [Poly(N,N'-dimethyl acrylamide)] has good
separation capability compared to LPA, and it does not require pre-coating. According to
past journal articles and reviews, these two polymers are currently in commercial use.
LongReadTM Matrix for Amersham Biosciences MegaBACETM is mostly to be LPA, while
POPTM matrix for Applied Biosystem ABI3700TM series is believed to be DMA.
Thermo-sensitive polymers and polymers with higher-order structure have the possibility
to reconcile deficiencies between high separation capability, short migration time, solution
viscosity and self-coating property, which LPA lacks. However any polymer exceeding
LPA has yet been developed. New polymerization techniques that can synthesize block
and graft copolymers using various water-soluble polymers and thermo-sensitive polymers
need to be developed for more advanced research.
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3.3 Experimental Section
3.3.1 Materials
Due to time and facility constraints, polymers were not synthesized in this project but
purchased from other laboratories. Table 2 shows the list of polymers used for this study.
Table 2 Polymer samples used for this experiment
Name Mw Appearance Vendor
POP7 n/a Solution in buffer ABI (Default polymer for ABI3730xl)
LPA 800k 600-1000k* 10% aq. solution Polysciences, Inc 2)
LPA 5000k -5000k 1% aq. solution Polysciences, Inc
DMA 100k 125k Powder Polymer Sources, Inc 3)
DMA 1000k 1010k Powder Polymer Sources, Inc
LPA-DMA
random 350k Powder Polymer Sources, Inc
copolymer
1) Weight averaged molecular weight, 2) http:l/hwww.polysciences.comlshop/, 3)http:l/www.polymersource.com/
3.3.2 Capillary Electrophoresis
Separations were studied using ABI3730xl instruments and performed with a standard
DNA sample, called BigDyeTM ver.3.1 (Applied Biosystems, Foster City, CA, USA).
Before injection, DNA was suspended in formamide, heated at 600C for 2 min for
denaturation, and then cooled on ice. Standard, thirty-six centimeters, uncoated fused-silica
capillaries were used. Polymer solutions were prepared in 1X running buffer solution for
ABI3730xl (Applied Biosystems). Each solution was mixed overnight in order to be
dissolved. Electrophoresis experiments were performed at 50, 60, and 70°C of the
separation temperature. The running voltage was changed among 8.5, 10.0, and 13.2kV,
which correspond to 236, 278, and 367 V/cm of the electric field, respectively. Since the
length of the capillary is 36cm. In most cases, the separation temperature was 600C and the
electric field was 278V/cm, except as otherwise noted. The electropherograms were
analyzed by fitting a Gaussian shape to the individual peak profiles using Fityk Software. 18
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18 http://www.unipress.waw.pl/fityk/
3.3.3 Chemical Analysis
3.3.3.1 Liquid Chromatography - Mass Spectrum (LC/MS) and Gas
Chromatography - Mass Spectrum (GC/MS) Measurement
Sample Preparation POP7 (0.4g) was precipitated in 15mL of methanol. Low
molecular weight additives were extracted from the precipitate by supersonication for 30
min. Supernatant of 1 and 2 were merged, filtrated and dried. The residual was dissolved in
water, filtrate with a 0.45[tm filter before being used for measurement. Measurement
conditions are summarized in Table 3 and 4.
Table 3 LC/MS Measurement Conditions
Parameters
Instrument (LC)
Column
Mobile Phase
Flow Rate
Injection Amount
Instrument (MS)
Ionization method
Measured Mass
Capillary Voltage
Cone Voltage
Source Block Temp
Desolvation Temp
Scanning Time
UV Wavelength
Table 4
Descriptions
Waters2690
Waters X-Terra MS C18 2.0 mmqpx15 mmx2.5 pm
Water/Methanol = 1/1
0.3 mL/min
10 pIL
Micromass Q-Tof
ESI Positive and Negative Mode
40-2000 amu
3,000 V(Positive), 2,500 V(Negative)
50 V
80°C
350°C
2 sec
280 nm
GC/MS Measurement Conditions
Parameters Descriptions
GC/MS Instrument HP5973MSD
Ionization El
Column DB-1 0.25mmqpx30m
Membrane thickness 0.251pm
Oven Temp 50°C (1min)->10C /min300°C (15min)
Injection Temp 300°C
Column Flow Rate 1mL/min
Injection Amount 1pL
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3.3.3.2 Nuclear Magnetic Resonance (NMR) Measurement
IH-NMR spectra and 13C-NMR spectra were measured with the Unity400 spectrometer
(Varian,Inc).
Qualitative Analysis Solvent was evaporated from the sample solution. Then D20
was added to the residual to prepare the NMR sample.
Quantitative Analysis H-NMR was measured with a double-tube (5mm in diameter).
The outside and inside tubes were filled with the sample solution as provided and
deuterated chloroform (NMR lock solvent), respectively. Due to the high proton
concentration, a single pulse was used to excite. Two runs were performed with 60 sec and
120 sec of waiting time, in consideration of the polymer sample's long relaxation time.
Confirmation of the SEC sample's chemical composition A part of the precipitate in
methanol was dissolved in water and used for the NMR sample. H-NMR was measured
with a double tube as the quantitative analysis.
3.3.3.3. Size Exclusion Chromatography (SEC) Measurement
A part of the precipitate in methanol was used for the SEC measurement. A sample
solution of O.lwt% was prepared with O.1M KH2PO4 pH=7, and then filtered with a
0.45tm PTFE filter. The measurement conditions are summarized in Table 5.
Table 5
Parameters
Instrument
Detector
Mobile Phase
Flow Rate
Injection
Column
Column Temp
Calibration Sample
Calibration Method
Calibration Curve
SEC Measurement Conditions
Descriptions
Tosoh HLC-8220 GPC(L)
RI (Incorporated)
0.1M KH2PO4 pH=7
1.OmL/min
O.lwt% x 100uL
TSKgel GMPWXL (30cmx2)
30°C
Single Dispersion PEG/PEO
Standard PEG/PEO
Cubic function
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3.4 Results and Discussions
3.4.1 Establishment of Experimental Protocol
In the beginning of the project, there was very little information about the polymer media
used with ABI3730xl, since no projects at the Broad Institute have addressed this issue in
the past. Moreover, ABI makes money not only from instruments but also from
consumables including polymer media and buffer solutions. Information on the proprietary
consumables has been kept secret from users like Broad.
Another problem was the highly-automated sequencing process at the Broad Institute. As
shown in Figure 12, output from this process emerges as a computer data file in ABI's
proprietary format, which can be handled only by the special software provided by the
company. The ABI format data includes the following information:
* Experimental conditions
· Raw data on the luminescent intensity of the four bases as a function of time
· The base code sequence as determined by the software named "Base Caller"
* Quality of base code sequencing accuracy (Q-value)
There are two problems with the ABI format data.
* Base Caller software is designed to label base code sequence and calculate
Q-values assuming standard running conditions (temperature, electric field,
polymer, etc) of ABI3730xl. When different polymer media are used, the base
coling and Q-value calculations do not make any sense.
· Raw data cannot be extracted and handled with common peak-fitting programs, and
the data are difficult to analyze manually.
28
Untouchable process
cIutpur
ABI
Fonnrmat
Data
Schematic diagram of the ABI3730x1 operational procedure
A: Base-calling Data B: Visualized Data
HII I
.... ..... ..  . ..... ....
...... ~ r .fs*srsz>'7 I. ,
Figure 13 Sample data after base calling. A: Base-calling results and Q-value; B:
Visualization. Base calling data correspond to the data shown in Figure 15, 16, and 17,
while the visualized data do not.
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The experimental project began by examining how to extract raw data from the ABI format
data and analyze them manually. With raw data, the resolution for certain peaks can be
calculated and the data quality among different experimental conditions can be compared.' 9
Research discovered the "org.biojava.bio.chromatogram" free computer software program
designed to handle raw data in the ABI format data file offered by BioJava, an open-source
project dedicated to providing a Java framework for processing biological data.20 Sample
raw data extracted using this software package is shown in Figure 15.
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Input
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Figure 14 Schematic diagram of the operational procedure used for this research
19 In most studies introduced in the previous chapters, researchers used old models of DNA sequencers
to acquire raw data. It is much easier to retrieve raw data from such old models.
20 http://www.biojava.org
http://www.biojava.org/docs/api/org/biojava/bio/chromatogram/package-summary.html
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ABI's standard DNA sample, "BigDye ver 3.1," was used throughout this research. Data
of Adenine fluorescent intensity were used to calculate resolution through these properties
because of strong fluorescent intensity, evenly distributed peak position, and constant data
quality resulting from the labeled dye's high durability. In order to elucidate the effects of
polymer media on the separation, selected peaks in the electropherogram raw data were
fitted using the nonlinear curve-fitting software, Fityk.2 ' Figure 16 shows BigDye Adenine
fluorescent data under standard conditions. The fluorescent peaks that correspond to the
following bases are used for fitting and calculating resolution: 53, 56, 105, 106, 108, 109,
160, 162, 263, 268, 318, 320, 423, 426, 567, 570, 640, 649, 724, and 730. These peaks are
marked by yellow circles in Figure 16.
Resolution was calculated using the following equation: 16
R N5 (trn2 - t m ,) tm 2 1
2 (tm2 +tm,) o AN
Where R, tml, tm2, a, and AN are resolution, migration time of peak 1, migration time of
peak 2, average peak width for peaks 1 and 2, and number of bases separating peaks 1 and
2, respectively. Using the best base-callers available, in optimal conditions, sequences can
typically be read at an accuracy of 98.5 to 99%, down to a resolution of 0.3.8
21 http://www.unipress.waw.pl/-wojdyr/fityk/
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Figure 15 Extracted raw electrophoresis data using ABI3730xl. Emission strength
(arbitrary unit) versus time for Guanine, Cytosine, Adenine, and Thymine from top to
bottom. The data were obtained using ABI's standard DNA sample, "BigDye ver 3.1,"
under standard running conditions (polymer media: POP7, electric field: 236V/cm, running
temperature: 60°C)
32
_ __
---- --
-
i
Ii
i
i
-- --' - --"-
I!
l
7 .. i.. f l F7 160, 162 ,
_: ..: ..::li ...................... ' - :?.:i,:, :.,,:.:::i::::::: ......... : i:ii:i e:v,,,
640, 649 724, 730 . .iii.ii.i:ii ..iiiiii:.i ::<i 8 i ! !!
. ':.' , : '' ' .i ::. ?:'.: iii -ii ~  ii i : I : i: ii ::i: 'ii:i ~ ?: ; ' ' ii:.ii :: iii:::i:.i:?.i:!:: iii :i: :: 2':i i i: i i ii!i ii. ~':::;i:: : ? 'eiii ii
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~............
~~~~~~UJ :fi:L..- _}_. .jY_ Mx t 4 -::¥ ...... ? ?t!~! iX 'iX?i '9||i , ,!i i Eii %'? ~ : ' '' g 'iii S? iii :!H :i$ i~i :ii~i~iiXH;? ~;~ , ilij' !i'L .
:: : : :::~ i:~:~ 'i:~~ !i S :~liD=!i !;'?!:: -.:' ::s!~,~i~,~
~
!? i~ii ~i i i Vi eNi.i-.!:ii:?. :.... , . i :....
2400 2450 2500 2550 2600 T l651s] 2700 2750 2800 2850 2900
Figure 16 Fluorescent data of"BigDye ver.3. 1" for Adenine. Peaks used for fitting
and calculating resolution are shown in the yellow circles. (polymer media, POP7; electric
field, 236V/cm; running temperature, 60°C).
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For typical DNA-sequencing operations, the quality of base-calling accuracy is expressed
by a Q-value.22 Defined by the following equation, Q-values are calculated by the
base-caller.
Q = -10 logio (p),
where p is the estimated error probability for the base-call. When a base-call has a
probability of 1/1000 of being incorrect, the Q-value is assigned as 30. The Broad Institute
secures 99% of base-calling accuracy or Q20 level of base calling quality.
Figure 17-A is the Q-value plot for the BigDye at Broad's standard running condition
(POP7, 236V/cm, 60°C) Under this condition, a base call below 700bp can clear a Q20
quality level. Figure 17-B shows the plot of resolution data manually calculated from the
same raw data. Comparing both plots, the author decided to consider R=0.4 the same level
of quality as Q20. It should be noted that although a rough relationship exists between Q20
and the resolution used in this project, the relationship is not linear and the degree of
correlation is fairly low. (See Figure 18.) The resolution defined in this research is useful
in examining data obtained under sub-standard conditions; however, to be used in in-depth
comparisons with Q-value, a more sophisticated way to calculate the resolution would be
required.
22 Ewing, B.; Green, P. Genome Research. 1998, 8, 186-194
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Figure 17 Comparison between Q-value (left) and Resolution (right). Both are
calculated from the raw data shown in Figure 15.
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Figure 18 Correlation between Resolution and Q-value. (DNA sample: BigDye
ver.3.1; polymer media: POP7; running temperature: 500C, 60°C and 70°C; electric field:
236V/cm and 278V/cm)
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3.4.2 POP7
ABI's default polymer, Performance Optimized Polymer ver.7, POP7, was chosen for the
first experiment of the project in order to confirm if the new data analysis method would
work with ABI3730xl. This experiment would also supply standard data, which could be
compared with data for other polymers. Data quality's dependence on temperature and
electric field was also investigated.
Figure 19 shows the sequencing data quality's dependence on temperature for POP7.
Resolution and Q-value were plotted versus base pair number (bp). Temperature ranged
from 500C to 700C, ABI's recommendation for sequencing operation; electric field was
fixed at 236V/cm. Within this temperature range, POP7 worked well and exhibited only
slight temperature dependence. Resolution begins to increase at around 0.6 at 50bp and
reaches it's maximum of R-1.0 at 200bp. It then decreases to its minimum of R=0.4 at the
base pair that is slightly longer than 700. The shape of the Q-value curve resembles the
shape of the resolution curve. Thus, the resolution analysis could be used instead of the
Q-value analysis. Figure 20 presents the resolution data plot as a function of migration
time. Migration speed also exhibits only a slight dependence on running temperature.
36
1.2 ISOCill:li: :i:?!? .: :ililil i i , 5o
0.
.6:! !-'! .......... :;: ? : i :.::xi: ~?I !'; i; ? :.....::. : !;::
0.4 2ik
0. ; ..: .. ' ::::.". : : :::::::: :? . .: : : ::.:!:!:':
0.
::°' ! ::: : ::::: ! : i? :::!:!:i i:e:=>::ii <ii'::: ::?i:i: :: ::!:::i 7
0.0 : '... .:.:..: :, .!:::i' " '::' :::::.:::]:::;:: ' :':::;
0 200 400 600 800
Base Number
7O
60
I
0 40
130
= 20
10
swe
--- 6oc
....... 70C
0 200 400 800 800 1000 1200
Bm Number
.... . ... ... . ............ ..... .. .. . ........ .. ............ .
Figure 19 Temperature dependence of Resolution (left) and Q-value (right) versus base
number. (Polymer: POP7, electric field: 236V/cm)
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Figure 20 Temperature dependence of resolution for each base. Resolution for each base
number is plotted versus migration time (left) and temperature dependence of migration
time for the 6 4 9th base (right). (Polymer: POP7, electric field: 236V/cm)
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Figure 21 shows the relationship between electric field and sequencing data quality for
POP7. Resolution was calculated for electric field of 236V/cm, 278V/cm, and 367V/cm,
while temperature was fixed at 600C. When comparing the resolution data at 236V/cm and
367V/cm, the data quality at the higher electric field seems inferior to the data quality at
the lower electric field. For example, the base number at R=0.4 is 730bp at 236V/cm,
while only 650bp at 367V/cm. On the Q-value plot, the read length at 367V/cm is
obviously shorter than those at 236V/cm and 278V/cm. (See Figure 21B.) Results from
both analyses are fairly consistent.
Figure 22 shows the effect of electric field on the migration time of electrophoresis. As
electric field increases, migration time quickly decreases. Since a very high electric field
deteriorates data quality, as shown in Figure 21, the electric field obviously affects the
relationship between data quality and migration time. Figure 23 demonstrates relationship
between the highest base number at a Q20 level of data quality and the maximum number
of runs per day.23 Assuming the number of bases at a Q20 or higher quality per day is
expressed by the product of the Q20 base number and the maximum number of runs per
day, it would be calculated as 20,000bp for 236V/cm, 23,000bp for 278V/cm, and
30,000bp for 367V/cm. In other words, even when quality deterioration is taken into
account, a higher electric field like 367V/cm would still improve the operation efficiency,
compared to the current setting of 278V/cm. The higher electric field could cause potential
disadvantages, such as heavier damage on the instruments, so more detailed studies are
required before this can be applied to practical operation.
No statistical treatments were conducted on the resolution analysis in this report. Since the
developed resolution analysis was carried out manually, a statistical approach would
unrealistically increase the workload. It should be noted that while this manual method is
useful for analysis of experimental data under extreme running conditions, it is not suitable
for analysis requiring high accuracy, such as running condition optimization.
23 This result is taken from the unpublished study conducted by James Meldrim in the Technology
Development group, Sequencing Operation Platform of the Broad Institute.
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3.4.3 DMA
DMA [poly(N,N'-dimethylacrylamide] was chosen as the second polymer after POP7
because it is widely believed to be the main ingredient of POP7, as mentioned in section
3.2.1.
Figure 24 shows the raw electropherogram data for BigDye measured with DMA100k.24
Peak separation was much poorer compared with POP7. Since most peaks could not be
determined, resolution could not be calculated. The solution viscosity of DMA100k was
also much lower than that of POP7. These results suggest that a molecular weight of 100k
is too low for this polymer. Electropherogram and resolution data for DMA with a higher
molecular weight (1000k) are shown in Figure 25 and 26, respectively. The peak resolution
is better than DMA100k, yet still worse than POP7, both for 5.0% and 7.5% concentration.
These results do not support the general belief that the main ingredient in POP7 is DMA.
Even for a 7.5% solution of DMA1000k, the peak resolution was still inferior to POP7.
ABI's researcher Dr. Madabhushi found an experimental result that a 6.5% solution of
DMA (molecular weight 98k) showed 600bp of read length in 125 minutes (resolution >
0.59). ° Since he noted that "the increase in DMA molecular mass beyond 98kDa slightly
improved the resolution but adversely increased the viscosity of the solution," the results
of this project would not be improved even if a higher molecular weight for DMA was
employed. It can be concluded that DMA is not the best polymer for DNA electrophoresis.
24 DMA100k is DMA polymer with an average molecular weight of 100kDa. See Table 2.
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Figure 25 Raw electrophoresis data for DMA1000k
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3.4.4 LPA
LPA (linear polyacrylamide) is one of the most widely used separation media in
DNA-sequencing due to its excellent performance in terms of read length and separation
time. Since LPA does not have self-coating capabiliteis, it is necessary to periodically
pre-coat the capillaries. Amersham's MegaBACE uses the high molecular weight,
LPA-based LongRead Matrix. In this section, the effects of polymer concentration,
temperature and electric field on the peak resolution of electropherograms are investigated
using a commercially available LPA with a molecular weight of 800k.
Figure 28 shows electropherograms measured with various concentrations of LPA800k
solution. In general, the peak resolution was better than with DMA. The relationship
between resolution and base number is shown in Figure 29. The best resolution was
obtained with 3.0wt/o solution; resolution decreases with both higher and lower
concentrations. LPA800k demonstrates a fairly good peak separation capability, but it is
still inferior to POP7, especially in longer bp regions. The resolution plot crosses the R=0.4
and R=0.3 lines at 500bp and 700bp, respectively. In the low bp region, meanwhile, the
resolution was even better than with POP7. The resolution versus time plot is shown in
Figure 29. The separation time for LPA800k is shorter than that of POP7, whereas the
separation time increases for higher concentration solutions.
The best explanation for these observations is that POP7 is not DMA but rather LPA,
perhaps with a slightly higher molecular weight than LPA800k. In that case, LPA could
potentially be used as a polymer medium for ABI3730xl after adjusting molecular weight
and other physical properties.
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Figure 27 Raw electrophoresis data for LPA800k. From top to bottom, polymer
concentration is 2.0, 2.5, 3.0, 3.5, 4.0 wtO/o. (Electric field 236V/cm, running Temperature
60°C.)
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Figure 28 Resolution of electrophoretic peaks measured with various concentrations of
LPA800k. (Electric field 236V/cm, running temperature 600 C.)
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Figure 29 Relationship between electrophoretic peak resolution and migration time
measured with various concentrations of LPA800k. (Electric field 236V/cm, running
temperature 60°C.)
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3.4.5 Chemical Analysis of POP7
Observations from previous sections suggest that a main ingredient in POP7 could be LPA.
To clarify this, chemical analysis was performed on POP7. Low molecular weight
additives were examined by Liquid Chromatography-Mass Spectroscopy (LC/MS) and
Gas Chromatography-Mass Spectroscopy (GC/MS). Nucleic Magnetic Resonance
Spectroscopy (1H-NMR and 13C-NMR) was used for qualitative analysis of polymeric
materials and quantitative analysis for all chemical species. Finally, Size Exclusion
Chromatography (SEC) was conducted to confirm the molecular weight distribution of
polymeric materials.
LC/MS A broad peak was observed at 0.99 minutes on MS-TIC (Total Ion
Chromatogram). Figure 30 shows the mass spectrum of this peak. The observed [M+Na]+
ion proved the existence of a chemical species with M=243. This chemical species is
supposed N-tris (hydroxymethyl)methyl-3-amino propanesulfonic acid (TAPS).
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Figure 30 MS for the peak at 0.99 minutes of retention time on MS-TIC
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GC/MS Figure 31 shows the GC/MS chromatogram of the pre-treated sample. The large
peak A is observed at 6 to 10 minutes on the GC spectrum. The lower part of Figure 36
shows the mass spectrum of peak A. Using spectrum library analysis, MS peak with M=44
was concluded to be Urea.
GC
I
Peak A
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Figure 31 GC for pre-treated sample of POP7 and MS for the Peak A (GC/MS)
48
k lre >
W..Ma' .+ XIr<.'
.WI ,
f^ ¢,I
!· _._L
IAS
44
.......1_· ___..... . __._ .. ___._._.. ._.ZL.L- I
., \o . .. "' "
1 3.
__
II ·
rl-.- tC
I 
~27
-TrTrrTT Tr . .oTs TTs rs
-'- ·· · · · -' ' 1- ' I11.1. 1- III. ' .... 1.1- 1- -I.. _: . -1 - .1 - .1 .... I ''I - - .- ;-. - ; ;
NMR Figures 32 and 33 show 1H and 13C-NMR spectra of POP7, respectively. Taking
both MS and NMR analyses into consideration, it was determined that Urea and TAPS are
involved in POP7 as low molecular weight ingredients. Peak assignments are drawn in
each Figure. From the analyses of the chemical shift and peak area, the main polymeric
ingredient of POP7 was determined to be LPA. Peaks at 2.95ppm in H-NMR as well as
175ppm and 36.5ppm in 13C-NMR seemed to be derived by the secondary polymer
component, DMA. Table 6 shows the component ratio of POP7 estimated from qualitative
'H-NMR analysis.
Table 6 Estimated ratio of each component for POP7 (wt%)
Ingredients wt%
Urea 37.6
TAPS* 1.7
LPA 1.7
DMA 0.04
H20 58.9
* TAPS is assumed as NaOH salt for calculation.
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Figure 32 H-NMR spectrum for POP7 (diluted by D20)
I 2
H2 N-C-NH 2
O
OH
CH2 14
H2 I H2
HO-C-C-NH--CH 2-- C--CH 2 -- S0 3-
131 H2 12 11 10
CH2
OH
2 0
H 21
-- C-CH 2 -I
30H 31
-- C-CH 2 -
_-rs
14
:10
13
i12 11
22 C=U 32 ,-Vu
2NH2 iN
H3 C 33 CH3 i 20
'30
! I
,;
1........ 10..0 . ...... 0... . . ... . .. ......
150 100 50
Figure 33 13C -NMR spectrum for POP7, magnified (diluted by D2 0)
50
2 H I21
-C-CH 2 -
22 C=O
23NH 2
30 H 31
-C--CH 2 -
32 C=O
H3C/ ,CH 3
14
a
I::
.I i ii
I/ "k, _,, l. i
1
22
,32
:i
21,31
~h J
PPIV
- - -- - - ------------ - .
6 4 2
·--- -cc.,.* U *\L _ II -.,.
SEC The molecular weight distribution of POP7 and LPA800k are measured as shown
in Table 7. Although the average molecular weights of these two LPA polymers were
almost the same, the molecular weight distributions were quite different. The molecular
weight distribution of POP7 is very small with only 1.8 on the polydispersity index (PDI),
while LPA800k has a rather broad distribution of 14 on PDI. LPA800k includes larger
amounts of low-molecular-weight polymer chains, which contribute to the resolution
inferior to that of POP7.
Table 7 Average molecular weight and polydispersity index for POP7 and LPA800k.
Polymer Mw Mn PDI
POP7 8.29 x 105 4.4 x 105 1.8
LPA800k 2.86 x 106 2.1 x 105 14
Identity of POP7 The chemical analysis results support the hypothesis from the
previous sections that POP7 consists mainly of LPA, although trace amounts of DMA are
also present. The DMA portion could be mixed or co-polymerized with LPA to give POP7
self-coating capabilities. While the average molecular weight was similar between POP7
and LPA800k, POP7's molecular weight distribution was much narrower, explaining
POP7's better resolution. POP7 include very common ingredients, like Urea and TAPS.
POP7 does not seem to be a complex polymer mixture, but rather a simple LPA polymer.
Hence, POP7 could be replaced by a low-cost, general-purpose LPA. Annual savings at the
Broad Institute were calculated $383,000 per year, if POP7 could be completely replaced
by a low-cost LPA800k. This corresponds to a 94.5% of reduction in polymer cost. 25
25 Suppose that the polymer concentration of POP7 is 3%. Since the price of POP7 solution is
$1,690.50 for one case (= 6 boxes = 30 bottles = 840 mL), lmL of POP7 solution would cost $2.01.
Hence, unit cost of POP7 (solid) would be $67.08 per gram. Meanwhile, since LPA800k (10% aqueous
solution, Polysciences, Inc.) costs $92.75 for one bottle, or 250g, the unit cost of LPA800k (solid) is
calculated to be $3.71 per gram. As Broad institute consumes 240 cases ($405,720) of POP7 every year,
possible saving producing polymers in-house would be $383,000 per year.
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3.4.6 Polymer Mixtures
POP7 is a mixture, or copolymer, of LPA and a trace amount of DMA. This composition
benefits from traits of both polymer, LPA and DMA, i.e. excellent peak separation and
self-coating capability. Thus, polymer mixture is appealing because it could satisfy various
requirements without the problems found with other polymers.
However, different polymers are usually immiscible. In fact, only one study has ever been
reported for DNA electrophoresis with a polymer mixture. 26 Examining different
combinations of LPA and DMA only a mixture of LPA with a trace amount of low
molecular weight DMA (0.2%, 8k Da)overcome the incompatibility of these two polymers.
In this section, DNA-sequencing with the LPA and DMA mixture is studied. It would be
expected that LPA/DMA block copolymer would work as a compatibilizer; however, it has
never been synthesized due to a lack of appropriate synthesis methods. In this experiment,
LPA/DMA random copolymer with 350k of molecular weight (COP350k) was tested as a
compatibilizer instead.
Figure 34 shows phase diagrams for LPA800k-DMA100k (A) and LPA800k-DMA1000k
(B). Only a low concentration of DMA100k alleviated incompatibility. The mixtures of
LPA800k (2.5%) and DMA100k (0.5%) does not show a significant difference from sole
LPA800k (2.5%) alone on the peak resolution of the electropherogram (Figure 35) . Since
the frequency of "unstable current errors," which are often observed when LPA is used
alone, was reduced to some degree, DMA may work as self-coating reagent.
Figure 36 is the phase diagram of LPA800k and COP350k. These two polymers phase
separate very easily. For example, 2.5% of LPA800k and 0.5% of COP350k temporarily
formed a pseudo-miscible solution, but then eventually gelled. Thus, COP350k did not
work as a compatibilizer for LPA and DMA. Figure 37 shows the electrophoretic
resolution for a mixture of 2.5% of LPA800k and 0.5% of COP350k; however, the
resolution is obviously worse than LPA800k (2.5%) alone. Poor compatibility of two
polymers further decreases resolution, as observed in previous research.
26 Song, L.; Liang, D.; Chen, Z.; Fang, D.; Chu, B. J. Chromatogr. A. 2001, 915, 231-239
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Figure 34 Phase diagrams for mixtures of LPA800k and DMAI00k (A), LPA800k
and DMA 1000k (B). 0, miscible; A, pseudo-miscible; x, immiscible.
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Figure 35 Resolution of electrophoretic peaks measured with a mixture of LPA800k
and DMA100k. (Electric field 236V/cm, running temperature 600 C.
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and COP350k. (Electric field 236V/cm, running temperature 600C.)
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3.5 Possible Approaches for the Future
In this project, focus was limited to the investigation of default polymers and several basic
polymers. However, the primary objective of this research at Broad should be trying to test
really cutting edge materials beyond the basic polymers. If Broad continues this study,
what approach would be favorable for further investigation?
One possible interesting approach would be the use of a thermosensitive polymer microgel.
A microgel is a hydrous polymer gel particle with a diameter ranging from tens of
nanometer to one micrometer. Only one research attempt utilizing polyacrylamide
microgel is known to date. However, it has not performed better than simple LPA.27 As
explained in section 3.2.2, some polymers have LCST or UCST and change their
hydrophilicity with temperature. Microgel particles made of such thermosensitive
polymers28 show phase transition between emulsion (with low solubility) and gel particle
(with high solubility), depending on temperature change. Taking advantage of this
behavior, it may be possible to inject a polymer as a low viscosity emulsion into a capillary,
while electrophoresis could be conducted through a robust gel network. In addition, if
core-shell particles consisting of a thermosensitive core and highly water-soluble shell
were prepared, electrophoretic performance could be even better than that of sole
thermosensitive microgel particles. Such microparticles have never been applied to DNA
electrophoresis.
PNIPAM microgel29 and Poly(N-ethylacrylamide) microgel30 are the only thermosensitive
microgels that have been prepared to date. Since both of them have LCST and their phase
transition occurs around room temperature, they are not suitable for application in DNA
electrophoresis, which is typically performed at around 50 to 70C. A problem with
synthesizing the UCST type of microgel is the need to develop a new polymerization
method. Microgel of LCST polymer like PNIPAM can be prepared by basic emulsion
polymerization or suspension polymerization because these polymers cannot dissolve in
water and they form an emulsion at polymerization temperature (typically more than 50°C).
27 Doherty, E. A. S.; Kan, C. W.; Barron, A. E.; Electrophoresis 2003, 24, 4170-4180
28 Pelton, R. Adv. Col. Interf Sci. 2000, 85, 1-33
29 For example, Jones, C. D.; Lyon, L. A. Macromolecules 2000, 33, 8301-8306
30 Lowe, J. S.; Chowdhry, B. Z.; Parsonage, J. R.; Snowden, M. J. Polymer 1998, 39, 1207-1212
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Most UCST polymers, such as PPE, cannot be polymerized by these polymerization
method and, thus, a new method should be considered first. This approach requires close
collaboration with synthetic polymer scientists.
Figure 38 Thermosensitive microgel
56
Thermosensitive Hydrogel
;mp HighLow TE
High Temp = Gel
Low Temp = Emulsion
**0 0 0*^:. :*8-I + 
3.6 Summary
In an effort to improve the operational efficiency of ABI3730xl, a DNA sequencer based
on multicapillary electrophoresis, effect of polymer media on electrophoresis performance
was investigated. The ultimate goal of this study is creating new polymer materials, which
allow the current genome-sequencing process higher throughput. In this research, as a first
step, various water-soluble polymers including POP7, LPA, and DMA were examined as
polymer media for the ABI3730xl.
Unfortunately, no polymers investigated in this research exhibited better capabilities than
the default polymer, POP7. However, it was confirmed that simple and inexpensive LPA
could replace POP7 with some optimization. The best results for lead length with such
alternative polymers were 500bp (R=0.4) or 700bp (R=0.3), while POP7 is 700bp (R=0.4).
New research procedures consisting of raw electropherogram data extraction, peak fitting,
and the calculation of peak resolution were established. Chemical analysis of POP7 was
conducted to show that the main ingredient of POP7 is not widely-believed DMA, but LPA
with a narrow molecular weight distribution. Possible future approach using
thermo-sensitive water-soluble polymer is proposed.
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4. Analysis of the Genome-Sequencing Tool Industry
4.1 Introduction
Through his internship at the Broad Institute, the author worked intimately with
ABI3730xl, and gained an appreciation for ABI's huge presence in the sequencing-tool
industry. ABI has maintained a monopoly over the industry since its emergence, and its
products have been the de facto standard in the genome-sequencing field. Interested in
ABI's dominant status in this relatively new business sector, the author conducted an
analysis of the genome-sequencing tool industry. Important questions raised include how
ABI's monopoly status has been established, whether its dominance will continue in the
future, and how the industry can develop in the future.
4.2 History of Genome-sequencing Technology4'31
The widely-accepted genome-sequencing technique, the Sanger method, was established
by Professor Fred Sanger of the University of Cambridge, who sequenced the complete
5,386-letter genetic code of a virus called PhiX174 in 1977. For this effort, he won his
second Nobel Prize in Chemistry in 1980, sharing it with Walter Gilbert of Harvard
University and Paul Berg of Stanford University. For a more detailed description of the
current DNA-sequencing precess, refer to Section 2.2.2.
Figure 38 illustrates the original Sanger method's procedure. Sanger originally employed a
radio isotope (RI) such as 32p and 35S to label dd-NTP reaction terminators. This method
requires four distinct PCR reactions to read out the base code of a single DNA. In the first
reaction, only A-type ddNTP was labeled by RI, then C, T, and G-types of dd-NTP were
RI-labeled for each subsequent reaction. These four reaction solutions were
electrophoresed in separated lanes on an acrylamide slab-gel. RI-labeled DNA fragments
were then detected with autoradiography.
31 Shreeve, J.; The Genome War - How Craig Venter Tried to Capture the Code of Life and Save the
World; Alfred A. Knopf: New York, 2004
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A problem with this method was the very low throughput to read bases. Only a limited
number of DNA could be analyzed simultaneously. In addition, each band had to be read
manually by a researcher. Thus the cycle time was almost one day, and operation
throughput was only hundred base pairs (bp) per day. Supposing this method were applied
to the human genome with three billion bp, it would take a hundred thousand years to read
all the base codes.
DNA to be read
, Electrophoresis (Slab-gel)
A C G T
Figure 38
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o (Read X-ray film
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o Using Sanger's method
on the human genome
would take 100,000
years.
Outline of the original Sanger method
In the wake of Sanger's innovation around 1980, a lot of researchers tried to automate the
Sanger method. For instance, five years prior to the start of the International Human
Genome Project, Professor Akiyoshi Wada of the University of Tokyo launched a project
among Japanese research institutes and companies in 1981.32 The project proposed a
prototype for an automatic DNA analyzer but was eventually dismissed after just three
32 In the Wada Project, Hitachi invented high-throughput detection technology, which was eventually
incorporated into ABI's products.
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years.33 Some American companies, like DuPont, also made some efforts to design an
automatic DNA sequencer, as did the American Department of Energy (DOE).
At the time, Applied Biosystems Inc., or ABI, established in 1981 by Professor Leroy
Hood and Dr. Mike Hunkapiller of California Institute of Technology, also worked on the
automation of the DNA sequencer. In 1986, Dr. Hunkapiller's younger brother Tim
invented the "four-color dye method," making the epoch that allowed ABI to successfully
launch the world's first automatic DNA sequencer, ABI Prism370A.
Figure 39 illustrates the "four color dye method." This method is characterized by the use
of four different colors of electron transfer dyes, instead of radioisotope, to label ddNTP.
Excited by a certain laser beam wavelength, these dyes illuminate four different colors
corresponding to the four different base nucleotides; i.e. they are green for Adenine, blue
for Cytosine, yellow for Guanine, and red for Thymine. The four-color method requires
only one PCR reaction and one lane of electrophoresis per single DNA sample. In addition,
since each band is automatically detected by a spectrometer, the operation is dramatically
more efficient than the original Sanger method. The cycle time of the sequencing operation
is less than six hours, while the daily throughput is 100bp - almost ten times shorter than
the original Sanger method.
After the "four-color dye method" was invented, several chemical and biological analysis
instrument companies conducted research on applying the multi-capillary electrophoresis
to DNA sequencers, instead of using the inefficient slab-gel electrophoresis. ABI again led
in the intense competition and finally released the world's first automatic, multicapillary
DNA sequencer ABI Prism3700 in 1997. DNA separation was carried out in a fused-silica
capillary (25 to 100 tm in diameter) filled with an aqueous solution of linear polymer,
instead of the acrylamide slab-gel. ABI Prism3700 was equipped with 96 capillaries and a
CCD detector, which allowed it to analyze 96 DNA samples simultaneously.3 4 Figure 40
33 Segawa, S., "Koshiba Project and Wada Project"(in Japanese),
http://www.mainichi-msn.co.jp/kagaku/rikei/column/news/20040531 org00m040002000c.html,
Mainichi Shimbun, May 31, 2004,
34 ABI established an alliance with Hitachi for access to its basic patent for detecting mechanisms as
well as precise control technology, including robotics and mechatronics, used for automating operations.
ABI has also contracted this Japanese electronics giant to manufacture the ABI3730xl.
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outlines ABI Prism3700's detection mechanism. Argon laser beam comes from lateral side
of the capillaries, while a perpendicularly-held CCD camera simultaneously detects
fluorescence from each capillary. In addition, the cycle time was drastically reduced, since
a higher electric field can be applied. For example, the cycle time of ABI's latest model
ABI3730xl is only one or two hours, and the sequencing throughput reaches almost
600,000bp per day. The third-generation sequencing technique really opened the door for
the deep investigation of human genome. Without the multi-capillary DNA sequencer,
neither the International Human Genome Project nor Celera Genomics would have
successfully finished by the 2001 deadline, or maybe they would have never started.
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4.3 Emergence of the Genome-Sequencing Tool Industry
Figure 41 illustrates the historical facts regarding genome-sequencing technology
development and the genome-sequencing tool industry. After the release of ABI370A, the
first automatic DNA sequencer powered by its proprietary four-color dye technology, ABI
successfully attained a monopolistic market position in the sequencing tool industry. Even
though a couple of competitors, like Molecular Dynamics (now Amersham Bioscience),
existed, ABI claimed almost 90% of the market share by 1995. ABI had already been
declared the dominating force in the genome research arena. "While the market was
specialized, Hunkapiller's enterprise was exploiting its dominant position so freely that its
customers grumbled that the abbreviation stood for 'Arrogance Beyond Imagination'." 3 ' In
1993, Perkin Elmer Corporation, a manufacturer of analytical and optical instruments, had
acquired ABI.
In 1997, when the high-throughput, multicapillary DNA sequencer ABI3700 was released,
the CEO of Perkin Elmer, Tony White, decided to bet the firm's future on this cutting edge
genome analysis technology. He spun off ABI from Perkin Elmer and established Celera
Genomics to start a new genetic information business powered by its high-throughput
DNA sequencer.3 5 ABI provided the ABI3700 sequencer not only to Celera but also to the
International Human Genome Project. Due to its excellent data quality, high throughput,
highly automated system, and wide technical support, ABI3700 quickly established a
dominant position in the sequencing tool industry.
35 The Perkin Elmer trade name and analytical and optical instrument business were sold off in 1999.
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Figure 41 Chronological diagram of the history of genome-sequencing technology
and the genome-sequencing tool industry.
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4.4 Analysis of the Genome-Sequencing Tool Industry
4.4.1 Industry S-curves
Figure 42 shows the S-curves for the genome-sequencing tool industry illustrated in terms
of daily throughput. Three S-curves correspond to the original Sanger method (first
generation), the four-color dye method (second generation), and the fully-automated,
multicapillary DNA sequencer (third generation), respectively. The first generation of
technology achieved only 100 bases per day, while the second and third generation
technologies achieved 1,000 and 600,000 bases of daily output. Thus, the four-color dye
method and the automatic multicapillary system can be considered "disruptive"
technologies to previous technologies. Note that Applied Biosystems developed both
disruptive technologies.
The industry currently seems subject to "natural technological limits." The current
multicapillary electrophoresis system has matured enough technologically, having gone
through eight years and one revision after the first product release in 1997. Considering
that the four-color dye method (2G) and the multicapillary system (3G) were released at
six and eleven years respectively after the release of the previous technology, the
next-generation technology could be released anytime now. In fact, various
next-generation sequencing technologies have already been studied in many
organizations.36 Such "fourth-generation" technologies include both straight extensions of
the current Sanger-type technology (e.g. Microelectrophoretic sequencing by the
Whitehead BioMEMS laboratory) and new sequencing methods based on alternative
technologies (e.g. Hybridization sequencing by Affymetrix and Perlegen, and
Pyrosequencing by 454 Corporation). The Dev department at the Broad Institute has long
worked with some of these research groups and companies to assess when such
technologies can be applied to its high-throughput genome-sequencing production facility.
Interestingly, ABI has not played an important role the next-generation of sequencing
technology. This means that ABI may not be able to maintain its current monopolistic
status in this industry, unless it is conducting in-house research behind-the-scenes or it
acquires a company that is conducting research on the next-generation technologies.
36 Shendure, J., Mitra, R. D., Varma, C., and Church, G. M., Nature Reviews, 2004,5, 335-344
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S-curves for the genome-sequencing tool industry
4.4.2 Uniqueness
Capture Value
and Complementary Assets to Create and
The first and largest value created in this industry is the invention of the Sanger method by
Professor Sanger of the University of Cambridge. Although he received the Nobel Prize
for this achievement, his invention went public and he himself has not captured any profit
value from the value creation.
Based on Sanger's ground-breaking technology, ABI has claimed virtually all the
technological achievement for both electrophoresis technologies and automation operation
systems. The three largest technological advancements made by ABI and its affiliates are
the four-color dye method, the self-coating polymer, the multicapillary detection system,
and the precisely controlled automation system. These technologies are patented by ABI
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Figure 42
and its affiliate, Hitachi. ABI created the second and third generation of sequencing
machines, based on these unique technologies.
ABI also built many sets of "complementally assets". ABI's business model goes beyond
simply selling instruments to customers. After selling the sequencer, ABI continues to
provide consumables, such as polymer solution, running buffer, standard DNA samples,
etc. These consumables are totally black-boxed. Yet, the quality of sequenced data
obtained with this package of expensive consumables is guaranteed by ABI. On-site
customer support is available for large customers. For example, ABI's on-site technicians
at the Broad are on call seven days per week. Other complementary assets include
production capability. Manufacturing of DNA sequencers are outsourced to Hitachi, a
Japanese leading electronics manufacturer. Working with Celera genomics and HGP for
long time, ABI also maintains a well-recognized brand in the biotech industry and research
communities. Table 8 summarizes ABI's technological uniqueness and complementary
assets.
Table 8 ABI's uniqueness and complementary assets
Uniqueness Complementary Asset
Proprietary Technology on Electrophoresis Customer support (7d/w)
- Four-color dyes labeling Total packaging including consumables
- Self-coating polymer Quality assurance
- Multicapillary detection system Manufacturing capability (Hitachi)
Automation technology (Hitachi) Brand
ABI not only created the most value for the second-, and third-generation technologies
through outstanding technological uniqueness, but it also captured this value by taking
advantage of strong complementary assets. Its collaboration with Hitachi plays a very
important role both for creating and capturing value. ABI has taken charge of research and
prototyping, while Hitachi has worked on system development and manufacturing. As an
original member of the Japanese national project, Hitachi has individually created value on
the automation of the DNA sequencer. Among ABI's technological uniqueness, the
multicapillary detection system and the precisely-controlled, automatic operation system
are Hitachi's proprietary technologies. Hitachi's rich experience in the production of
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precisely-controlled, automatic mechatronics systems has also been considered an
important complementary asset.
Figure 43 shows the Uniqueness-Complementary Assets matrix for the
genome-sequencing tool industry. Since uniqueness is fairly easy to maintain through
registering patents and tightly holding complementary assets, this industry can be placed in
"The Big Win" category. This means that the industry allows a limited number of
companies to attain large-scale success within their realms, even allowing companies, like
ABI, to establish easily monopolistic status.
Although the industry has so far created much value, it may not have sufficiently captured
it yet. ABI seems to successfully capture most present potential industry earning (PIE),
however the current market is still limited to research. It is unclear if ABI can continue to
capture the most value when the market extends to the medical and diagnostics markets in
the future. Then, the next-generation of technology could dominate the industry.
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Figure 43 Henderson's Uniqueness vs. Complementary Assets Matrix
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4.4.3 Industry Structure - Present and Future
4.4.3.1 Five Forces Analysis for Current Industry
The five forces analysis for the current genome-sequencing tool industry is presented in
Figure 45.
Rivalry among existing firms: None
The industry is monopolized by ABI. This position is supported by both technological
uniqueness and complementary assets as described in the previous section.
Supplier's power: Very low
From ABI-Hitachi's viewpoint, suppliers are merely vendors of general components and
materials, such as CCDs, lasers, pumps, electric power units, plastic plates, polymeric
materials, etc. Since the number of sequencers produced is very small, ABI-Hitachi cannot
afford to customize any components, and by necessity, they use a typical grade of
components. Hence, the only difference among suppliers is price.
Buyer's power: Medium
Currently only public and private research institutions are customers. PIE still remains
small and is even shrinking after the completion of the Human Genome Project due to
reducing government funds for genome-sequencing research. (Many research institutions
rely on government funds to purchase expensive DNA sequencers.) Requests for price
discounts are fairly strong, given the strong competition among genome centers to obtain
government funding. On the other hand, there are virtually no alternative products and
buyers cannot help but buy ABI's products eventually. Most of the DNA sequencers are so
automated and black-boxed that buyers must rely on the companies in the industry for
maintenance, etc.
Threat of new entrants: Very low
The market is relatively small and now shrinking. The current technology has matured, and
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the leaning curve effect for incumbents cannot be neglected. Both ABI's technological
uniqueness and complementary assets are very strong, and the entrance barrier is very
high. Entrance would be easier with more inexpensive technology.
Threat of substitute products or services: Low
At this point, the threat of substitute products is fairly low. Cheap alternative technologies
are, however, currently under development by some research groups, such as the
Whitehead BioMEMS laboratory, Affymetrix, Illomina, 454 Corporation, etc., whereas
ABI does not seem to be working on such next-generation technologies. In the future, the
fourth-generation sequencing technology may replace ABI's market presence, which is
based on third generation technology.
4.4.3.2 Industry Evolution
In the near future, two radical transformations are expected in this industry. One is a
change of customers, and the other is the emerging fourth-generation technologies.
Although the current customer base is limited to public and private research institutes and
PIE is still small, companies in the healthcare industry, such as pharmaceutical companies
and hospitals, have long been expected to be the new customer base of this industry. This
huge market forecast had actually been the persuading argument to bring much
government and private funding into this industry during the HGP era. Recent research
shows, however, that will take longer than predicted for the healthcare industry to become
a new customer.
In the healthcare industry, genome-sequencing technology will be utilized for the single
nucleotide polymorphisms-based diagnostics (SNP, pronounced "snip"). "SNP" is the
technical jargon for a single-letter mutation or coding error on the genomic code. SNPs are
subtle and seemingly random variations among the smallest components of genes
(nucleotides). Some inherited SNP variations are believed to cause genetically-based
diseases and others are responsible for genetically-inherited characteristics like eye color.
The SNP discovery challenge is to find the individual genetic building blocks that
correspond to various illnesses; this information may then lead to cures through gene
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therapy. 37
Figure 46 shows an example of SNPs-based diagnostics. Assume that there are three SNPs
related to Alzheimer's disease and persons with SNP1, SNP2, and SNP3 have a 20%, 10%
and 5% higher risk of Alzheimer's disease. The person who has all three of the SNPs may
have a 100% higher risk of the disease. Since 99.9% of human genes are common, SNPs
are just 0.1% of human gene, but it still corresponds to three million of base pairs. Many
researchers are now pursuing the challenge of discovering all important SNPs, but it will
take quite a while before enough information, including interactions among each SNPs, is
collected.
The genome-sequencing tools market for diagnostic purposes will open when SNP-based
diagnostics have been sufficiently realized to be useful for at least one disease. The
industry will have to wait quite a bit to open this huge market. It is not clear if ABI can
maintain its current advantage, both in technological uniqueness and complementary
assets, until then, given upcoming fourth-generation technology.
Reference
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Figure 46 Schematic illustration of SNPs-based diagnostics
37 Wolff, G., The Biotech Investor's Bible, New York, John Wiley & Sons, Inc., 2001
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4.4.4 Value Chain and Boundaries
Figure 47 shows the value chain for the genome-sequencing tool industry. In addition to its
original strength in basic research and product packaging, ABI has established a strong
sales capability, including customer support and consumable sales. In addition, through its
collaboration with Hitachi, ABI has also integrated an assembly (manufacturing)
capability. Through this vertical integration, ABI has successfully captured most of the
value which had been historically created in the industry. On the other hand, other players
in the industry are typically small research organizations or start-up companies, which tend
to remain in basic research and product packaging.
As discussed in the previous section, the structure of the value chain currently does not
seem very dynamic. Only with a disruptive technology, could a new player be able to step
into ABI's current position, although it will not be so easy to defeat ABI by only
technological uniqueness. To appeal to customers who feel comfortable with ABI's
integrated service offering, the new company would need to establish a set of
complementary assets, perhaps through another vertical integration.
ABI Hitachi ABI
Vertical Integration
Figure 47 Value chain for the genome-sequencing tool industry
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4.4.5 Strategy for the Future of ABI
After the completion of the "Genome War" - the Human Genome Project competition,
Craig Venter, the former CEO of Celera Genomics, was fired. Celera and ABI are now
managed under the same umbrella by Applera Corporation, the stock-holding company for
two of the most outstanding companies in the genomics arena. Current management is
focusing on genome-based diagnostics with synergy from Celera and ABI. Celera
Diagnostics, a joint venture between Celera and ABI is now making every effort to
develop new SNP-based genomic diagnostics, competing among world leading research
institutes and start-up companies. However, this strategy only aids the decline of ABI and
Celera's stock prices.
Due to recent serious financial concerns, ABI reduced its workforce by 3.5%, or 145
employees in the first fiscal quarter of 2005. Many of the eliminated positions were in
research and development (R&D), but the sales and manufacturing departments were also
impacted. ABI had made even more drastic workforce reductions in December 2002,
laying off five hundred employees, however, those cost reductions had little effect on
relative spending as a percentage of revenues, and little impact on earning growth.
Business conditions remain challenging, and lack of revenue growth still remains ABI's
number one dilemma.
Considering ABI's outstanding technological uniqueness in the genome-sequencing
technology and its outstanding complementary assets acquired through vertical integration,
the author recommends that ABI should try to remain the number one provider of
genome-sequencing tools even when next-generation technology becomes available. ABI
should invest more on next-generation sequencing technology with much higher
throughput and greater cost advantage, instead of waiting for somebody else to discover
whole SNPs information, opening the door to new genomic diagnostics. ABI may want to
concentrate more on in-house basic research or invest in hopeful start-up companies, such
as 454 Corporation, which are doing research on the different technologies within ABI's
technological competency.
ABI should also work more with potential customers, such as healthcare management
organizations (HMOs), health insurance companies, and pharmaceutical companies. Using
already known SNPs information, ABI can work with those companies to estimate disease
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occurrence risk more accurately. Although the number of known SNPs is still few, such
activities would help the company establish a bridge with the future genomic diagnostic
market, which could be another complementary asset of ABI.
4.5 Summary
In the genome-sequencing tool industry, there were three technological innovations to date.
The first one was made by a Nobel laureate, and the next two were both derived by ABI.
Based not only on outstanding technological uniqueness, but also strong complementary
assets, ABI established monopolistic status in the industry. To build complementary assets,
ABI has vertically integrated several components in the value chain, including
manufacturing capability and technological support.
After the accomplishment of the Human Genome Project, however, ABI is struggling with
low profitability and a diminished impetus for future growth. The reason is, contrary to
early optimistic forecasts, the market's expansion to the whole healthcare industry will be
delayed. Based on this industry analysis, the author recommends that ABI should focus
more on next-generation genome-sequencing technology to maintain its current
monopolistic position even in the upcoming genomic diagnostics period.
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5. Conclusion
Recent advances in information technology, bioengineering techniques, and
data-processing methodology have opened the door to modem research approaches to
genomics and have inspired ambitious efforts, like the International Human Genome
Project. Playing a main role in the HGP, the Broad Institute established the
genome-sequencing capability with the world's highest level of throughput. Even after the
completion of the HGP, the Broad Institute continues to address improvements in
sequencing throughput with an eye toward future genomics-based medication.
In the pursuit of operational efficiency, the author attempted to find a way to improve the
efficiency of the genome sequencer, an instrument that reads a DNA base code through
capillary electrophoresis technology, which plays a central role despite certain obstacles in
the whole genome-sequencing process.
Chapter 3 examined polymer media, a determining factor in sequencing throughput, that is
used for the electrophoresis, to Figure out how it could be modified from the current
standard. This was the first attempt of this sort at the Broad Institute. The methodology
employed here involved the following stages.
1. Study past research efforts about polymer media
2. Establish a new experimental protocol to handle other polymers
3. Analyze the chemical composition of ABI's default polymer (POP7)
4. Run genome-sequencing on several polymer materials to learn how they work
Conducting research on past studies, the author learned that LPA and DMA are known as
the best polymers for DNA electrophoresis, and that many water-soluble polymers
demonstrate an inferior performance compared to these basic polymers. Although
structured polymers have the possibility to work better than simple acrylamides, the lack of
polymerization technique still remains a hurdle for implementation.
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The author introduced a new method to extract raw data from the sequencer's highly
black-boxed internal process, which allows analyzing electrophoretic performance under
various running conditions. This new analysis makes a wide variety of further
investigations on ABI3730x1 possible beyond the new polymer research.
A chemical analysis of the current default polymer media, POP7, showed that it consists
mainly of LPA, although a trace amount of DMA was detected. This DMA could be mixed
or co-polymerized with LPA for self-coating purposes. The average molecular weight of
POP7 was around 800k with relatively narrow distribution. Thus, POP7 could be replaced
by a low-cost, general purpose LPA. Assuming POP7 were completely replaced with
LPA800k, the annual cost reduction at the Broad Institute was calculated to be possibly
$383,000 per year, which corresponds to a 94.5% reduction in the current polymer cost.
Chapter 4 revised the genome-sequencing technology and analyzed the
genome-sequencing tool industry to learn how ABI established its current monopolistic
status. ABI achieved two of the three technological innovations. By succeeding on
building strong complementary assets based on outstanding technological uniqueness, ABI
currently enjoys monopolistic status in the industry. In order to build complementary
assets, ABI vertically integrated some components in the value chain, including
manufacturing capability and technological support.
After the completion of the Human Genome Project, however, ABI seems to be struggling
with low profitability and little technological advantage for future growth. This is due to
the fact that their customer base still remains only in research institutes, and that market
expansion to the healthcare industry will take longer than predicted. Based on the industry
analysis, the author recommends that ABI should focus more on the next-generation of
genome-sequencing technology to allow the company to maintain its current monopolistic
position in the future genomic medication market.
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